<?xml version="1.0" encoding="UTF-8"?>
<p>To our knowledge, this is the first work that assesses the risk of DDIs with various regimens in various time periods and also the first that considers the most recent DAA regimens as well as relevant DDI mechanisms. It shows that despite improved newer antiviral regimens, the frequency of significant real-world DDIs in a changing epidemiology of HCV patients has not declined, but remained stable. Therefore, careful assessment of patientsâ€™ regular outpatient medications and individual evaluation for potential DDIs seem as important as ever.</p>
